Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.

Affiliation

Xie X(#)(1), Liu Y(#)(1), Liu J(#)(2)(3), Zhang X(1), Zou J(1), Fontes-Garfias CR(1), Xia H(1), Swanson KA(4), Cutler M(4), Cooper D(4), Menachery VD(2)(3), Weaver SC(2)(3), Dormitzer PR(5), Shi PY(6)(7)(8)(9)(10).
Author information:
(1)Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
(2)Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
(3)Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX, USA.
(4)Pfizer, Pearl River, NY, USA.
(5)Pfizer, Pearl River, NY, USA. [Email]
(6)Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA. [Email]
(7)Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX, USA. [Email]
(8)Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, USA. [Email]
(9)Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA. [Email]
(10)Sealy Center for Structural Biology & Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, USA. [Email]
(#)Contributed equally

Abstract

Update of bioRxiv. 2021 Jan 27;: